In the first quarter, the production and sales growth of the pharmaceutical industry was gratifying, and the total output value increased by more than 50%

 In the first quarter of 2022, China's pharmaceutical industry will continue to implement technological innovation, rationally increase production capacity, and continue to strive for production.
The industry-wide production and sales growth trend is gratifying
.
It is estimated that in the first quarter, the total industrial output value of the pharmaceutical industry increased by 54% year-on-year, and the new output value reached 2.
6 billion yuan by nearly 1 billion yuan
.
Realize an increase of more than 40% in added value
.
In addition, since April, pharmaceutical companies have also successively announced their first-quarter 2022 performance reports
.
Many companies also expressed gratifying performance
.
For example, China Resources Pharmaceutical announced on the Hong Kong Stock Exchange on April 25 that China Resources Sanjiu, a 63.
6%-owned subsidiary of the company, achieved a year-on-year increase of 2.
8% in operating income in the first quarter of 2022 to 4.
194 billion yuan; net profit increased by 30.
5% year-on-year to 846 million yuan Yuan
.
At the same time, in the first quarter of 2022, the company's actual control of 21.
95% of the subsidiary Jiangzhong Pharmaceutical achieved a year-on-year increase of 37.
52% in operating income to 931 million yuan; net profit rose by 19.
41% year-on-year to 194 million yuan; in addition, the company indirectly held shares of 28.
86 In the first quarter of 2022, China Resources Boya Bio’s total operating income increased by 4.
9% year-on-year to about 655 million yuan; net profit increased by 2.
8% year-on-year to 107 million yuan
.
On April 23, Huaren Pharmaceutical released its first quarterly report for 2022.
In the first quarter, the company's operating income increased by 12.
27% year-on-year to 385 million yuan, and the net profit attributable to shareholders of the listed company increased by 0.
86% year-on-year to 25.
0396 million yuan
.
Xinhua Pharma released a first-quarter results announcement on the evening of April 19, saying that revenue in the first quarter of 2022 increased by 3.
57% year-on-year to about 1.
831 billion yuan; net profit increased by 8.
2% year-on-year to about 109 million yuan
.
In addition, in the first quarter of 2022, Zuoli Pharmaceutical achieved a year-on-year increase of 29.
18% in revenue, about 439 million yuan; net profit increased by 56.
97% year-on-year, about 68.
7467 million yuan
.
Regarding the performance growth of Zuoli Pharmaceutical, the company said that it has seized the opportunity of the country to promote the inheritance, innovation and development of traditional Chinese medicine and cultivated a number of core products.
Wuling Capsules, Bailing Tablets and Lingze Tablets have all entered the National Essential Medicine List
.
The stable and good performance is not only due to the rapid growth of the revenue scale of the main products Wuling Capsules, Bailing Tablets and Lingze Tablets, but also, with the improvement of profitability, the company has more abundant funds, the scale of loans is reduced, and the financial Costs are further reduced
.
In the first quarter of 2022, Aoxiang Pharmaceutical achieved a year-on-year increase of 42.
45% in operating income to 205,113,465.
95 yuan; net profit attributable to shareholders of listed companies increased by 61.
18% year-on-year to 70,722,644.
75 yuan
.
The company stated that the main reasons for the growth of operating income during the reporting period were: 1.
The company's business maintained steady growth, especially the CDMO business, gout, and nervous system businesses grew rapidly; 2.
International business increased by 67% over the same period last year
.
The increase in net profit was mainly due to the increase in net profit brought about by the growth of the company's business
.
In the first quarter of 2022, Qianhong Pharmaceutical’s operating income increased by 41.
16% year-on-year to 550 million yuan; the net profit before and after non-deduction attributable to shareholders of listed companies in the same period increased by 135.
93% and 55.
75% year-on-year, respectively 1.
3% 100 million yuan and 76.
38 million yuan
.
It can be seen that in the first quarter, Qianhong Pharmaceutical achieved a substantial increase in overall performance
.
The prospectus shows that Qianhong Pharmaceutical’s products mainly include medicines [limited to tablets, hard capsules, granules, APIs, freeze-dried powder, freeze-dried powder injections (including anti-tumor drugs), small-volume injections, and diagnostic testing reagents.
Production and sales (except those involving pre-approval); acquisition of agricultural and sideline products (except for special regulations); leasing of own facilities; self-operated and agency import and export of various commodities and technologies
.
In the first quarter of 2022, Livzon Group's revenue increased by 3.
86% year-on-year to 3.
479 billion yuan; net profit attributable to the parent increased by 6.
47% year-on-year to 553 million yuan; net profit attributable to the parent after deduction increased by 15.
61% year-on-year to 5.
61 100 million yuan, higher than the growth rate of 13.
66% last year
.
The announcement shows that Livzon Group's chemical preparations and API business have achieved varying degrees of growth
.
Among them, the chemical preparation business achieved sales income of 2.
109 billion yuan, a year-on-year increase of 10.
90%, showing good performance
.
Specifically, digestive tract products achieved revenue of 1.
070 billion yuan, a year-on-year increase of 5.
90%
.
Judging from the performance reports released by various companies, the performance of many companies in the first quarter of 2022 is gratifying, and the momentum of growth has continued, bringing a good start to the development of the industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.